All PlansCoverageMedium impact
07.11.02f, Measurement of Exhaled Nitric Oxide and Breath Condensate in the Diagnosis and Management of Asthma and Other Respiratory Disorders
Independence Blue Cross·Pulmonology, Allergy & Immunology, Pediatrics +1 more·Medical Policy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
Policy 07.11.02f addresses the measurement of exhaled nitric oxide (FeNO) and breath condensate testing for asthma and respiratory disorder diagnosis and management. This is a reissued policy effective October 1, 2025. The billing team must review the full policy document to identify specific coverage determinations, prior authorization requirements, and affected CPT/HCPCS codes for these diagnostic procedures.
Action Required
By October 1, 2025: Billing team must obtain and review the complete policy text from the provided URL to identify: (1) specific CPT/HCPCS codes covered for FeNO and breath condensate testing, (2) prior authorization requirements, (3) medical necessity criteria, and (4) any billing or documentation requirements. Update billing system rules, encounter forms, and provider communication accordingly. Without the full policy details, specific codes and requirements cannot be extracted—contact the payer or policy administrator immediately to obtain complete policy documentation.